Study finds experimental coagulant risk for heart patients

08/30/2011 | Reuters

The addition of experimental anti-clotting drug darexaban to anti-platelet therapy resulted in a two- to fourfold increase in bleeding among patients with acute coronary syndrome, a Phase II study found. The oral factor Xa inhibitor is undergoing a test for stroke prevention in subjects with atrial fibrillation and previously showed promise in reducing blood-clot risk after orthopedic surgery.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice-President of Technology and Regulatory Affairs
AdvaMed
Washington DC, DC
Sr Product Manager Global Marketing (US/DA/00/0085/SL) - 14000009V3
Abbott
Chicago, IL
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Vice President, Information Technology
HealthPartners
MN